FDA approves AbbVie’s upadacitinib for giant cell arteritis
The approval of the therapy is backed by the outcomes from the randomised Phase III SELECT-GCA trial.
Approvals
FDA approves Abeona’s $3.1m cell therapy for rare skin disease
UK MHRA authorises BridgeBio’s acoramidis for ATTR-CM
EC conditionally approves Regeneron’s Lynozyfic for multiple myeloma
J&J’s Tremfya gains EC marketing authorisation for ulcerative colitis
China approves InnoCare Pharma’s BTK inhibitor for lymphoma
FDA approves Akeso’s monoclonal antibody for nasopharyngeal carcinoma
EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy
